Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...